Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Latest From Pfenex Inc.

Ligand Set For Partnership Opportunities After Completing On Pfenex

Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.

Deals Companies

Ligand Set For Partnership Opportunities After Completing On Pfenex

Fresh from completing its acquisition of Pfenex, Ligand Pharmaceuticals has laid out the benefits that it expects to gain from the deal.

Deals M & A

What’s Next? Five Things To Look Out For In October

In October, the period during which Mylan may complete its merger with Upjohn will begin, while the FDA will begin holding monthly stakeholder meetings ahead of the third iteration of the Generic Drug User Fee Amendments program, also known as GDUFA III.

Deals Intellectual Property

Merck Sprints Toward Late 2020 Filing For Pneumococcal Vaccine V114

Merck’s 15-valent vaccine candidate was non-inferior to Pfizer’s Prevnar 13 in a Phase III study and provided superior protection against serotype 3, a frequent cause of invasive pneumococcal disease. 

Clinical Trials Vaccines
See All

Company Information

  • Industry
  • Research, Analytical Equipment & Supplies
  • Pharmaceuticals
    • Generic Drugs
    • Vaccines
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
    • Synthesis Technologies, Production Processes
UsernamePublicRestriction

Register